Adding SIRT to chemotherapy can improve survival in colorectal cancer

Share This Post

Colorectal cancer

The researchers found that adding SIRT to chemotherapy can improve the survival rate of colorectal cancer

New research shows that for patients with colorectal cancer who have only liver metastases or mainly liver metastases, adding selective in vivo radiotherapy based on standard first-line mFOLFOX6 chemotherapy can significantly increase the median overall survival time of patients with primary tumors on the right.

Professor Guy van Hazel of the University of Western Australia said: “Our findings do require further validation, so we can consider early use options for patients with primary liver tumors with metastatic colon cancer (mCRC) that have only liver metastases or predominantly liver metastases. Sexual in vivo radiotherapy (SIRT). “He added:” These findings are good news for patients with right-sided tumors. They have a worse prognosis and fewer treatment options than patients with left-sided tumors. “

The location of the mCRC primary tumor is an important prognostic factor and predictor of treatment response. For example, a 2016 study showed that patients with primary tumors on the right side had poorer response and prognosis than patients with primary tumors on the left side.

Testing the efficacy and safety of SIRT

SIRT is a form of in vivo radiotherapy for Y-90 resin microspheres, which is administered through an intrahepatic artery catheter. Beta radiation microspheres preferentially reach the microvascular system around the tumor, which can reduce systemic effects.

The SIRFLOX, FOXFIRE and FOXFIRE global studies were used to evaluate the efficacy and safety of first-line oxaliplatin-based chemotherapy plus SIRT for unresectable mCRC. In the combined analysis, 554 patients received chemotherapy plus SIRT, and 549 patients received chemotherapy only. The median overall survival time was 22.6 and 23.3 months, respectively. In the post-mortem analysis, the location of the primary tumor was prospectively obtained on the cohort case report form. The right tumor was defined as any primary tumor at the proximal end of the splenic flexure, and the left tumor was defined as any tumor at the splenic flexure, farther from the colon or Primary tumor in the rectum.

SIRT plus chemotherapy can prolong survival time

The results showed that the median overall survival time of patients with mCRC left tumors was 24.6 months in the chemotherapy plus SIRT group, and 26.6 months in the chemotherapy alone group. However, the median overall survival time of mCRC right tumor patients was 22 months in the chemotherapy plus SIRT group, and 17.1 months in the chemotherapy alone group. The standard statistical test of the treatment effect on overall survival time by location also proves that the tumor side is more significant.

One hypothesis is that right-sided tumors not only have a poorer prognosis, they are more resistant to chemotherapy, and may be more sensitive to radiation therapy with a completely different mechanism of action.

The lack of positive results in the overall analysis may be due to the inclusion of patients with extrahepatic tumor metastases. Although SIRT can control liver disorders, it cannot control extrahepatic disorders. 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy